277 related articles for article (PubMed ID: 31584362)
21. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.
Kessel A; Haj T; Peri R; Snir A; Melamed D; Sabo E; Toubi E
Autoimmun Rev; 2012 Jul; 11(9):670-7. PubMed ID: 22155204
[TBL] [Abstract][Full Text] [Related]
22. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
23. Allergy-related changes in levels of CD8+CD25+FoxP3(bright) Treg cells and FoxP3 mRNA expression in peripheral blood: the role of IL-10 or TGF-beta.
Eusebio M; Kuna P; Kraszula L; Kupczyk M; Pietruczuk M
J Biol Regul Homeost Agents; 2014; 28(3):461-70. PubMed ID: 25316133
[TBL] [Abstract][Full Text] [Related]
24. The potential role of the thymus in immunotherapies for acute myeloid leukemia.
Hino C; Xu Y; Xiao J; Baylink DJ; Reeves ME; Cao H
Front Immunol; 2023; 14():1102517. PubMed ID: 36814919
[TBL] [Abstract][Full Text] [Related]
25. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
26. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
27. Targeting Treg cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
[TBL] [Abstract][Full Text] [Related]
28. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.
Zhang S; Ke X; Zeng S; Wu M; Lou J; Wu L; Huang P; Huang L; Wang F; Pan S
Cell Mol Immunol; 2015 Sep; 12(5):580-91. PubMed ID: 26166762
[TBL] [Abstract][Full Text] [Related]
29. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.
Mousavi-Niri N; Naseroleslami M; Hadjati J
Hum Vaccin Immunother; 2019; 15(3):620-624. PubMed ID: 30633616
[TBL] [Abstract][Full Text] [Related]
30. Role of CD4
Hariyanto AD; Permata TBM; Gondhowiardjo SA
Immunol Med; 2022 Jun; 45(2):94-107. PubMed ID: 34495808
[TBL] [Abstract][Full Text] [Related]
31. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
32. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children.
Ajduk J; Marinic I; Aberle N; Rabatic S; Gagro A
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):314-22. PubMed ID: 18450115
[TBL] [Abstract][Full Text] [Related]
33. Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25
Wilkinson DS; Ghosh D; Nickle RA; Moorman CD; Mannie MD
Front Immunol; 2017; 8():1782. PubMed ID: 29312311
[TBL] [Abstract][Full Text] [Related]
34. Intranuclear interactomic inhibition of FoxP3 suppresses functions of Treg cells.
Park JH; Ko JS; Shin Y; Cho JY; Oh HA; Bothwell AL; Lee SK
Biochem Biophys Res Commun; 2014 Aug; 451(1):1-7. PubMed ID: 25044110
[TBL] [Abstract][Full Text] [Related]
35. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
36. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
38. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
Chen W; Jin W; Hardegen N; Lei KJ; Li L; Marinos N; McGrady G; Wahl SM
J Exp Med; 2003 Dec; 198(12):1875-86. PubMed ID: 14676299
[TBL] [Abstract][Full Text] [Related]
39. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
40. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
